ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
Why Astra won’t find bladder cancer domination easy
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
